52 results about "Proto-Oncogenes" patented technology

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof) that degrades Proto-oncogene VAV 1 protein (VAV1). The chemical entities are useful for treating subjects having a disorder or disease that can be treated by reducing the level of VAV1, such as cancer, inflammatory or autoimmune disorders.

The present disclosure relates to compounds that elicit degradation of proteins directed against the protooncogene tyrosine protein kinase receptor (RET), which may be a wild-type RET or a mutant form of RET, including compounds of formula (I), for use in the treatment of diseases and conditions mediated by said proteins. # imgabs0 #

The invention discloses a method, a system and equipment for detecting internal tandem repeat and a storage medium, and the key points of the technical scheme are as follows: obtaining a first reference sequence according to at least one target exon sequence corresponding to a protooncogene, and obtaining a second reference sequence according to at least one target intron sequence corresponding to the protooncogene; comparing the sequencing data of the to-be-detected sample to the second reference sequence to obtain a first comparison result, extracting an uncompared sequence from the sequencing data according to the first comparison result, and comparing the uncompared sequence to the first reference sequence to obtain a second comparison result; and determining a first detection result according to the second comparison result and a first reference sequence, and performing false positive filtering on the first detection result to obtain a second detection result. According to the invention, false positive can be reduced so as to ensure the accuracy and reliability of subsequent analysis.

The disclosure features chemical entities (e.g., compounds or pharmaceutically acceptable salts thereof) that degrade the protooncogene VAV 1 protein (VAV1). These chemical entities are useful, for example, in the treatment of subjects suffering from inflammatory or autoimmune disorders (e.g., human subjects).

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof) that degrades Proto-oncogene VAV 1 protein (VAV1). The chemical entities are useful for treating subjects having a disorder or disease that can be treated by reducing the level of VAV1, such as cancer, inflammatory or autoimmune disorders.

Provided is reproducible means that enables production of nucleus pulposus progenitor cells (preferably, an active nucleus pulposus progenitor cell phenotype) from desired cells such as terminally differentiated cells and stem cells having pluripotency or multipotency. A nucleus pulposus progenitor cell inducer according to the present invention comprising an effective amount of a gene of Brachyury (T) or a homolog thereof, at least one selected from the group consisting of SRY-box6 (SOX6) or a homolog thereof and Forkhead Box Q1 (FOXQ1) or a homolog thereof, and MYC Proto-Oncogene, BHLH Transcription Factor (cMyc) or a homolog thereof (nucleus pulposus progenitor cell master regulator transcription factor), or a product thereof.

The present disclosure features chemical entities (e.g., compounds or pharmaceutically acceptable salts thereof) that degrade the proto-oncogene VAV1 protein (VAV1). The chemical entities are useful, for example, for treating subjects (e.g., human subjects) with inflammatory or autoimmune disorders.

The present invention discloses a method and system for mining potential proto-oncogenes based on the three-dimensional structure of chromatin, which relates to the field of computational biology technology. The method comprises: obtaining multiple mutation insulation regions based on chromatin data and cancer mutation data, and inputting the regions into a trained binding site predictor to obtain prediction results and destroyed insulation regions; obtaining multiple differentially expressed gene sets based on cancer gene expression data, intersecting the multiple differentially expressed gene sets to obtain a final differentially expressed gene set; intersecting the final differentially expressed gene set and the genes in the destroyed insulation regions to obtain intersection genes; performing survival analysis to obtain analysis results, screening the intersection genes based on the analysis results to obtain genes associated with poor prognosis; and screening the intersection genes to obtain potential proto-oncogenes. This improves the accuracy and reliability of mining potential proto-oncogenes while saving time and economic expenses.

The present invention includes a method and kit for method for detecting anti-Ro antibody negative Sjögren's syndrome / Sjögren's disease without performing a lip biopsy comprising: obtaining a biological sample from a patient suspected of having an anti-Ro antibody negative Sjögren's syndrome / Sjögren's disease; and detecting if the biological sample has autoantibodies to at least one of: Geminin DNA Replication Inhibitor (GMNN), Kelch Domain Containing 8 A (KLHDC8A), Microtubule Associated Protein RP / EB Family Member 1 (MAPRE1), Nucleoporin 50 (NUP50), or SKI Like Proto-Oncogene (SKIL).

A novel compound that is a protein degradation-inducing part of the proto-oncogene tyrosine protein kinase receptor (RET), wherein the RET may be wild-type RET or a mutant form of RET.

Methods and compositions for gene therapy of retinal degeneration related to mutations in MER proto-oncogene, tyrosine kinase (MERTK).

The application relates to a circular triplex-forming oligonucleotide, a preparation method and application in preparation of tumor-targeting drugs. The circular triplex-forming oligonucleotide (Cir-TFO) is composed of two oligonucleotide chains A and B, each of which comprises a first complementary sequence, a first connecting sequence, a target sequence, a second connecting sequence and a second complementary sequence from the 5' end to the 3' end. The first complementary sequences of the two oligonucleotide chains A and B are reversely and complementarily connected, and the second complementary sequences are reversely and complementarily connected to form a closed ring structure. The target sequence is a TFO sequence capable of forming a triplex structure with double-stranded DNA in the promoter region of a target gene through Hoogsteen hydrogen bonds, and the target gene is selected from a proto-oncogene, an anti-apoptotic gene or a tumor metabolism-related gene.

The invention discloses a pharmaceutical composition containing radix astragali, radix salviae miltiorrhizae, radix salviae miltiorrhizae and fructus schizandrae and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicine, the pharmaceutical composition containing radix astragali, radix salviae miltiorrhizae, radix salviae miltiorrhizae and fructus schizandrae is prepared from the following raw materials in parts by weight: 30-50 parts of radix astragali, 15-30 parts of radix salviae miltiorrhizae, 15-30 parts of radix codonopsis, 15-30 parts of radix pseudostellariae, 3-5 parts of fructus schizandrae and 10-15 parts of radix et rhizoma rhei. Preferably, the oral medicine dosage forms capable of being prepared comprise hard capsules, tablets and granules. According to the application disclosed by the invention, the expression levels of p38MAPK, JNK and ERK proteins, c-fos mRNA and c-jun mRNA of myocardial tissues of rats in a medicine group are lowest, so that the medicine disclosed by the invention can be used for inhibiting the activity of an MAPK signal channel of the myocardial tissues and inhibiting the expression of related protooncogenes c-fos and c-jun so as to inhibit myocardial fibrosis. Therefore, the medicine can effectively improve the cardiac function of a DCM model rat and relieve myocardial damage, and the effect of the medicine is related to inhibition of MAPK signal channel activity.

The present disclosure relates to proteolysis-inducing compounds against the proto-oncogene tyrosine-protein kinase receptor (RET), which may be either wild-type RET or a mutant form of RET, which are useful in the treatment of diseases and disorders mediated by said protein, and have formula (I): TIFF2025540907000060.tif43113

Provided herein are compounds of formula (I) and salts and compositions thereof which find utility as modulators of Cbl-b in the treatment of various forms of cancer.

The invention relates to a cyclic three-strand-forming oligonucleotide, a preparation method and application in preparation of a tumor targeting drug, the cyclic three-strand-forming oligonucleotide (Cir-TFO) is composed of an oligonucleotide chain A and an oligonucleotide chain B, and each oligonucleotide chain sequentially comprises a first complementary sequence, a first connection sequence, a target sequence, a second connection sequence and a second complementary sequence from the 5'end to the 3 'end; the first complementary sequences of the oligonucleotide chain A and the oligonucleotide chain B are in reverse complementary connection, and the second complementary sequences of the oligonucleotide chain A and the oligonucleotide chain B are in reverse complementary connection to form a closed ring structure; the target sequence is a TFO sequence which can form a three-chain structure with double-chain DNA of a target gene promoter region through a Hoogsteen hydrogen bond, and the target gene is selected from a protooncogene, an anti-apoptosis gene or a tumor metabolism related gene.

TIFF2025540906000076.tif4057 The present disclosure relates to protein-binding compounds of the proto-oncogene tyrosine-protein kinase receptor (RET), which may be either wild-type RET or a mutant form of RET, that are useful for the treatment of diseases and disorders mediated by said protein and have formula (I):

The present application relates to the field of cancer cell identification, and particularly relates to a method and system for identifying different types of cancer cells of a renal pelvis cancer patient based on urine, the method comprising: collecting a urine sample, obtaining a detection sample by using the urine sample; sequencing the detection sample to obtain a cell expression profile of the detection sample; obtaining cell expression profile data of a mixed urothelial cell subpopulation by using the cell expression profile, the mixed urothelial cell subpopulation comprising normal urothelial cells and cancerous urothelial cells; extracting different proto-oncogene expression data from the cell expression profile data of the mixed urothelial cell subpopulation; analyzing the different proto-oncogene expression data to obtain a cancer cell ratio and identify different types of cancer cells. The present method quickly and accurately obtains different types of cancerous urothelial cells through non-invasive examination and proto-oncogene expression profile data, and provides a reference and basis for preoperative neoadjuvant therapy of renal pelvis cancer.

The invention described herein provides antibodies or antigen-binding fragments thereof, or polypeptides comprising the same (such as CAR in CAR-T cells), which can be useful for, for example, in treating certain cancer that expresses / over-expresses RET proto-oncogene, for treating certain cancer that expresses / over-expresses RET proto-oncogene, such as NB, AML, small cell lung cancer, Ewing sarcoma, breast cancer, and other cancer types with RET expression. The antibodies or antigen-binding fragments thereof of the invention are also useful for detection of RET expression / overexpression, and related diagnostic use.

The present disclosure relates to compounds that elicit degradation of proteins against the protooncogene tyrosine protein kinase receptor (RET), which may be a wild-type RET or a mutant form of RET, for use in the treatment of diseases and disorders mediated by said proteins and having formula (I). # imgabs0 #

The present disclosure provides compounds of formula (I): which induce proteolysis of the proto-oncogene tyrosine protein kinase receptor (RET), which may be either wild-type or mutant RET (useful in the treatment of diseases and disorders mediated by said protein): This relates to the compound represented by TIFF2026506696000135.tif42150.

The present disclosure relates to CRISPR-related systems and components for targeting, editing and / or modulating the expression of FLI-1 (Freund Virus Leukemia Integration 1 Transcription Factor; Fli-1 prooncogene, ETS Transcription Factor) genes. The disclosure also relates to methods and uses thereof related to engineered cells comprising T cells or T cell precursors.

The invention relates to a combination of a third-generation EGFR tyrosine kinase inhibitor and a bispecific antibody that comprises a first variable domain that can bind an extracellular part of human epidermal growth factor receptor (EGFR) and a second variable domain that can bind an extracellular part of human MET Proto-Oncogene, Receptor Tyrosine Kinase (cMET) for use in a method of treatment of a cancer in a subject.

The invention provides a lentiviral vector for constructing a cell model for detecting carcinogenicity of chemical substances, a recombinant cell as well as a preparation method and application of the lentiviral vector. The lentiviral vector comprises a human c-myc gene promoter, an operably connected reporter gene and a selection marker gene. Recombinant cells capable of stably expressing reporter genes can be obtained by transfecting host cells with the vector, the activation effect of chemical substances on c-myc channels can be sensitively reflected through signal changes of the reporter genes, and rapid and visual preliminary screening of carcinogenicity is achieved. Furthermore, the recombinant cell is combined with a CRISPR-Cas9 sgRNA library targeting DNA damage repair, epigenetic regulation, tumor inhibition and proto-oncogene to construct an integrated screening system, so that the carcinogenic potential of chemical substances can be evaluated, key genes and molecular mechanisms of genetic toxicity of the chemical substances can be systematically revealed, and the application prospect is broad. And an efficient tool is provided for toxicology risk assessment and mechanism research.

This disclosure relates to CRISPR-related systems and components for targeting, editing, and / or regulating the expression of the FLI-1 (Friend virus leukemia integration 1 transcription factor, Fli-1 proto-oncogene, ETS transcription factor) gene. This disclosure also relates to methods and applications relating to genetically modified cells, including T cells or T cell progenitor cells.

The invention relates to an application of a specific excitation Mas receptor in a medicine for preventing and treating hepatic ischemia-reperfusion injury. According to the invention, a G protein coupled receptor Mas coded by a protooncogene Mas1 is focused, a 70% warm ischemia reperfusion model of the liver is constructed by clamping left and middle leaf vessels of the liver by a vascular clamp after a mouse is laparotomy, and the condition that the liver injury can be obviously alleviated by activating the Mas receptor and the liver injury can be aggravated by knocking out the Mas receptor is fully proved on an in-vivo level; the invention provides an important early-stage data basis for research and development of new drugs based on specific activation of the Mas receptor, and is expected to provide an important animal experiment basis for development of new drugs aiming at the Mas receptor in a later stage.

The invention as disclosed herein relates to bispecific antibodies that comprises a first variable domain that can bind an extracellular part of epidermal growth factor receptor (EGFR) and a second variable domain that can bind an extracellular part of MET Proto-Oncogene, Receptor Tyrosine Kinase (cMET). The antibody may comprise a common light chain. It may be a human antibody. The antibody may be a full length antibody. In some embodiments the bispecific antibody is an IgG1 format antibody having an anti-EGFR, anti-cMET stoichiometry of 1:1. In some embodiment the antibody has one variable domain that can bind EGFR and one variable domain that can bind cMET.

The present invention relates to bispecific antibodies comprising a first variable domain that can bind to an extracellular portion of the epidermal growth factor receptor (EGFR) and a second variable domain that can bind to an extracellular portion of the MET proto-oncogene, tyrosine kinase receptor (cMET). The antibody may comprise a common light chain. It may be a human antibody. The antibody may be a full-length antibody. In some embodiments, the bispecific antibody is an IgG1-format antibody having a 1:1 anti-cMET, anti-EGFR stoichiometry. In some embodiments, the antibody has a variable domain that can bind to EGFR and a variable domain that can bind to cMET.

Disclosed herein are compounds and compositions having potency in the modulation of Myc family proteins. Such compounds and compositions can be used in the treatment of proliferative diseases, such as cancer, or in the treatment of disease where modulation of Myc family proteins is desired. Also disclosed herein are methods of using said compounds and compositions.

Methods and compositions are provided for gene therapy of retinal degeneration associated with MER proto-oncogene, i.e. Tyrosine kinase (MERTK) mutations.